CN101160321A - Q3 sparc缺失突变体及其用途 - Google Patents

Q3 sparc缺失突变体及其用途 Download PDF

Info

Publication number
CN101160321A
CN101160321A CNA200680012446XA CN200680012446A CN101160321A CN 101160321 A CN101160321 A CN 101160321A CN A200680012446X A CNA200680012446X A CN A200680012446XA CN 200680012446 A CN200680012446 A CN 200680012446A CN 101160321 A CN101160321 A CN 101160321A
Authority
CN
China
Prior art keywords
sparc
polypeptide
antibody
composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680012446XA
Other languages
English (en)
Chinese (zh)
Inventor
V·特里鲁
N·P·德塞
P·索恩-希翁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
American Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Bioscience Inc filed Critical American Bioscience Inc
Publication of CN101160321A publication Critical patent/CN101160321A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA200680012446XA 2005-02-18 2006-02-17 Q3 sparc缺失突变体及其用途 Pending CN101160321A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65426105P 2005-02-18 2005-02-18
US60/654,261 2005-02-18

Publications (1)

Publication Number Publication Date
CN101160321A true CN101160321A (zh) 2008-04-09

Family

ID=37000156

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680012446XA Pending CN101160321A (zh) 2005-02-18 2006-02-17 Q3 sparc缺失突变体及其用途

Country Status (7)

Country Link
US (3) US7332568B2 (https=)
EP (1) EP1869077A2 (https=)
JP (1) JP2008535475A (https=)
CN (1) CN101160321A (https=)
AU (1) AU2006237613A1 (https=)
CA (1) CA2598510C (https=)
WO (1) WO2006112930A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102576016A (zh) * 2009-09-18 2012-07-11 阿布拉西斯生物科学有限责任公司 Sparc微环境标签在癌症治疗中的应用
CN103221062A (zh) * 2010-06-03 2013-07-24 阿布拉西斯生物科学有限责任公司 外周血sparc 结合抗体及其用途
CN104174025A (zh) * 2008-12-05 2014-12-03 阿布拉西斯生物科学有限责任公司 Sparc结合肽及其应用
US9193782B2 (en) 2010-06-03 2015-11-24 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2509365C (en) * 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
US8440625B2 (en) 2006-06-26 2013-05-14 University Of British Columbia Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
JP2011516609A (ja) * 2008-04-14 2011-05-26 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ抗炎症活性及びその使用
AU2013228006B2 (en) * 2008-12-05 2016-05-12 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
BRPI0922789A2 (pt) * 2008-12-05 2019-10-15 Abraxis Bioscience Llc peptídeo de ligação de albumina intermediador para reconhecimento de doença
WO2010105097A2 (en) * 2009-03-11 2010-09-16 Abraxis Bioscience, Llc Sparc angiogenic domain and methods of use
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270961B1 (en) * 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5128247A (en) * 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5130423A (en) * 1990-07-13 1992-07-14 Microprobe Corporation Non-corrosive compositions and methods useful for the extraction of nucleic acids
CA2155186A1 (en) * 1993-02-01 1994-08-18 Kevin M. Ulmer Methods and apparatus for dna sequencing
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5945515A (en) * 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
CA2278678A1 (en) * 1997-01-31 1998-08-06 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
US6316193B1 (en) * 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US20040018188A9 (en) 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US6387664B1 (en) * 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
WO2001081631A1 (en) 2000-04-25 2001-11-01 Dna Sciences, Inc. Detection of nucleotide sequence variations via the proofreading activity of polymerases
WO2002090544A2 (en) 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
US6919504B2 (en) * 2002-12-19 2005-07-19 3M Innovative Properties Company Flexible heat sink
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
JP2007525167A (ja) * 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
EP2784082B1 (en) 2004-05-14 2017-12-27 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel.

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104174025A (zh) * 2008-12-05 2014-12-03 阿布拉西斯生物科学有限责任公司 Sparc结合肽及其应用
US9308279B2 (en) 2008-12-05 2016-04-12 Abraxis Biosciences, Llc SPARC binding ScFvs
US9314537B2 (en) 2008-12-05 2016-04-19 Abraxis Bioscience, Llc SPARC binding ScFcs
CN104174025B (zh) * 2008-12-05 2017-01-11 阿布拉西斯生物科学有限责任公司 Sparc结合肽及其应用
CN104127879B (zh) * 2008-12-05 2017-05-10 阿布拉西斯生物科学有限责任公司 结合SPARC的scFv
US10053504B2 (en) 2008-12-05 2018-08-21 Abraxis Bioscience, Llc SPARC binding ScFvs
CN102576016A (zh) * 2009-09-18 2012-07-11 阿布拉西斯生物科学有限责任公司 Sparc微环境标签在癌症治疗中的应用
CN103221062A (zh) * 2010-06-03 2013-07-24 阿布拉西斯生物科学有限责任公司 外周血sparc 结合抗体及其用途
US9193782B2 (en) 2010-06-03 2015-11-24 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer

Also Published As

Publication number Publication date
CA2598510A1 (en) 2006-10-26
US7332568B2 (en) 2008-02-19
US20060199248A1 (en) 2006-09-07
EP1869077A2 (en) 2007-12-26
CA2598510C (en) 2011-12-20
JP2008535475A (ja) 2008-09-04
US20110009337A1 (en) 2011-01-13
WO2006112930A3 (en) 2007-04-05
US20080182258A1 (en) 2008-07-31
WO2006112930A2 (en) 2006-10-26
AU2006237613A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
CN101160321A (zh) Q3 sparc缺失突变体及其用途
US20250282888A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP6586412B2 (ja) ｐ９７のフラグメントおよびその使用
TWI438004B (zh) 半胱胺酸工程化之抗ｔｅｎｂ２抗體及抗體藥物共軛物
CN102281890B (zh) Sparc结合肽及其应用
US9623116B2 (en) Antibody-light fusion products for cancer therapeutics
US10167328B2 (en) Methods for cancer therapy using mutant light molecules with increased affinity to receptors
WO2018071777A1 (en) Innate immune cell trispecific binding proteins and methods of use
CN103747807A (zh) P97-抗体缀合物和使用方法
CN101925612A (zh) 针对癌相关的nfkbib变体的表位的抗体及其用途
CN102482347A (zh) 修饰抗体组合物及其制备和使用方法
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
KR20230107239A (ko) 항 b7-h3 항체-약물 콘주게이트 투여에 의한 중피종의 치료
US20250304681A1 (en) Anti-rage antibody, extracellular vesicle, and preparation method and use thereof
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
US20210379147A1 (en) Method and system for treating cancer utilizing tinagl1
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
JP2020515286A (ja) 癌を処置する抗体コンストラクトおよび方法
US20210046149A1 (en) Bifunctional blood brain therapies
US20220144906A1 (en) Bifunctional blood brain therapies for interleukin-1 related diseases
CN114585647A (zh) 抗grp78抗体及其使用方法
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
EP4665769A2 (en) Lair-1 agonistic antibodies and methods of use thereof
TW202409080A (zh) 用於治療卵巢癌之組合療法
WO2026043932A1 (en) Constructs that selectively bind phosphatidylserine and their use in detecting and treating disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080409